So Young Life Sciences Corporation's robust R&D program includes three key technologies, for which So Young has filed both US and foreign patent applications.
In August 2017 the company filed an initial patent application claiming production of non-tumorigenic induced Pluripotent Stem Cells (iPSCs), with Mr. Avinash Seth as the sole inventor. The process can utilize virtually any somatic cell (body cell), and doesn't rely on viruses as the vector delivery mechanism for cellular reprogramming. Being non-tumorigenic, these iPSCs promise to unlock the true potential of stem cells in organogenesis and Regenerative Medicine. With proper tissue engineering techniques any organ could potentially be resurrected. An international application (PCT) was filed in August 2018, PCT/US18/47458, and was published in February 2019 ( (WO 2019/040583). National phase applications have been filed in China, European Patent office (EPO), India, Japan, UAE, and the USA.
In July 2018 the company filed an initial patent application claiming a technique for treating breast and pancreatic cancer cells. According to inventors Mr. Avinash Seth, Mr. Nikko Lowe and Mr. Robert Fish, the technology involves using liposomes (a nanosized gene delivery system) that contain both a potent tumor suppressor protein, and the gene that encodes the tumor suppressive protein. In vitro experiments have demonstrated that the liposomes were capable of inducing greater than 95 percent cancer cell death of the aforementioned cancer cell lines, and reduced their proliferation rate by 91 percent. The results are particularly promising because these aggressive cancer cell lines were resistant to multiple conventional methods of treatment, including administration of chemotherapeutic agents, radiation and other anti-cancer molecules. An international application (PCT) was filed in July 2019, PCT/US2019/40156, and was published in January 2019 (WO 2020/023183). National phase applications have been filed in China, European Patent office (EPO), India and the USA.
In April 2019 So Young Life Sciences Corporation and the Indian Multi-Billion Dollar FMCG (Fast Moving Consumer Goods) Conglomerate DS Group India Pvt Ltd. formed a joint venture to develop a smokeless tobacco product that would reduce the risk of smokeless tobacco consumers from developing lung and throat cancer. This project resulted in the creation of a parent independent company, Gamot Global Pvt Ltd, headquartered in Singapore. Gamot Global owns the corresponding intellectual properties, which encompassed the area of developing smokeless tobacco products and other derivatives from a health care standpoint. Preliminary evidence is that the novel smokeless tobacco products and derivatives are able to suppress the growth of human lung cancer cells and throat cancer cell lines by ninety percent. In addition, it appears that the added compositions in these smokeless tobacco products do not affect the growth of healthy human lung cells and tissue. Both US and international (PCT) patent applications were filed in May 2020. The PCT application, PCT/US20/31849, was published November 2020 as WO 2020/227512.